Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma

Patients with gastric and esophageal (GE) adenocarcinoma tumors in which the oncogene ERBB2 has been amplified are routinely treated with a combination of cytotoxic chemotherapy and the ERBB2-directed antibody trastuzumab; however, the addition of trastuzumab, even when tested in a selected biomarke...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Kim, Jihun, Fox, Cameron, Peng, Shouyong, Pusung, Mark, Pectasides, Eirini, Matthee, Eric, Hong, Yong Sang, Do, In-Gu, Jang, Jiryeon, Thorner, Aaron R., Van Hummelen, Paul, Rustgi, Anil K., Wong, Kwok-Kin, Zhou, Zhongren, Tang, Ping, Kim, Kyoung-Mee, Lee, Jeeyun, Bass, Adam J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4348950/
https://ncbi.nlm.nih.gov/pubmed/25401468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI75200
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados